Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists

US10538567B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Martin Bossart · Frankfurt am Main, DE
• Andreas Evers · Frankfurt am Main, DE
• Torsten Haack · Frankfurt am Main, DE
• Dieter Kadereit · Kelkheim, DE
• Katrin Lorenz · Frankfurt am Main, DE
• Michael Wagner · Frankfurt am Main, DE
• Stefania PFEIFFER-MAREK · Frankfurt, DE
• Martin Lorenz · Frankfurt am Main, DE

Key dates

• Filing date: Dec 1, 2017
• Grant date: Jan 21, 2020
• Expiry date: Feb 1, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.